MCID: TMP003
MIFTS: 61

Temporal Arteritis

Categories: Rare diseases, Cardiovascular diseases, Nephrological diseases, Bone diseases, Neuronal diseases, Muscle diseases, Oral diseases

Aliases & Classifications for Temporal Arteritis

MalaCards integrated aliases for Temporal Arteritis:

Name: Temporal Arteritis 54 12 50 51 56 14 69
Polymyalgia Rheumatica 12 56 52 41 42 14 69
Giant Cell Arteritis 12 50 51 56 41 42 69
Cranial Arteritis 50 51 69
Rhizomelic Pseudopolyarthritis 56 69
Horton's Giant Cell Arteritis 50
Polymyalgia Rheumatica [dup] 12
Horton's Temporal Arteritis 50
Giant Cell Arteritis Nos 12
Arteritis Temporalis 50
Arteritis Cranialis 50
Horton's Arteritis 50
Horton’s Syndrome 50
Horton's Disease 12
Horton’s Disease 50
Horton Disease 56
Gca 50

Characteristics:

Orphanet epidemiological data:

56
giant cell arteritis
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Germany),1-5/10000 (United Kingdom),1-5/10000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
temporal arteritis:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Temporal Arteritis

MedlinePlus : 41 giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. it narrows the arteries, which keeps blood from flowing well. giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. both are more common in women than in men. they almost always affect people over the age of 50. early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. other symptoms include headaches pain and tenderness over the temples double vision or visual loss, dizziness problems with coordination and balance pain in your jaw and tongue your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. there is no single test to diagnose giant cell arteritis, but you may have tests that measure inflammation. treatment is usually with corticosteroids. early treatment is important; otherwise there is a risk of permanent vision loss or stroke. however, when properly treated, giant cell arteritis rarely comes back. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Temporal Arteritis, also known as polymyalgia rheumatica, is related to chlamydia and polyarteritis nodosa, and has symptoms including visual impairment, optic atrophy and nystagmus. An important gene associated with Temporal Arteritis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Prednisone and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include testes, tongue and skin, and related phenotype is immune system.

NIH Rare Diseases : 50 giant cell arteritis (gca) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. in gca, the vessels of the head are most involved (especially the temporal arteries, located on each side of the head), but other blood vessels can also become inflamed. the inflammation causes the arteries to narrow, resulting in poor blood flow. signs and symptoms may include a throbbing headache on one side of the head or the back of the head; tenderness of the scalp; various symptoms that feel like the flu; and/or problems with eyesight. the cause of gca is still being studied, but an abnormal immune response has been implicated. several genetic and environmental factors may increase a person's risk to develop gca. early treatment is important and may include corticosteroids and/or other medications that suppress the immune system. last updated: 4/5/2016

NINDS : 51 Vasculitis is inflammation of blood vessels, which includes the veins, arteries, and capillaries. It occurs when the immune system mitakenly attacks a blood vessel. Vasculitis can also be caused by other immune system disease, an allergic reaction to medicines or toxins, and by certain blood cancers that trigger an immune system reaction. The resulting reduced blood flow can permanently damage the brain, spinal cord, peripheral nervous system, and other organs and tissue. Some forms of vasculitis affect a particular organ, whie others may affect many organs at the same time. Symptoms include headaches (especially a headache that doesn’t go away), fever, weight loss, confusion or forgetfulness leading to dementia, swelling of the brain, pain, vision problems, trouble speaking or understanding, muscle weakness and paralysis, and seizures. Some of the better understood vasculitis syndromes are temporal arteritis (also called giant cell arteritis or cranial arteritis--a chronic inflammatory disorder of large blood vessels) and Takayasu’s disease, which affects larger aortas and may cause stoke.

Wikipedia : 72 Giant-cell arteritis (GCA), also called temporal arteritis, is an inflammatory disease of blood vessels... more...

Description from OMIM: 187360

Related Diseases for Temporal Arteritis

Diseases in the Temporal Arteritis family:

Juvenile Temporal Arteritis

Diseases related to Temporal Arteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
id Related Disease Score Top Affiliating Genes
1 chlamydia 30.9 CD40LG IFNG
2 polyarteritis nodosa 30.4 CRP IFNG SMUG1
3 hypereosinophilic syndrome 30.0 HLA-DRB1 IFNG
4 choroiditis 29.2 CCL2 CRP IL6
5 myofascial pain syndrome 28.9 CCL2 CCL5 IL6
6 lymphoma 28.6 APOH CD40LG IFNG IL6 TNFRSF10A
7 myocardial infarction 28.2 CCL2 CCL5 CD40LG CRP IL6
8 atherosclerosis 27.3 CCL2 HLA-DRB1 IFNG IL1RN IL6 PTPN22
9 rheumatoid arthritis 26.2 CCL2 CCL5 CD40LG CRP HLA-DRB1 IFNG
10 juvenile temporal arteritis 12.5
11 rhizomelic pseudopolyarthritis 12.2
12 retinal vasculitis 11.3
13 nonarteritic anterior ischemic optic neuropathy 11.1
14 vasculitis syndromes of the central and peripheral nervous systems 10.9
15 acromesomelic dysplasia 10.9
16 acquired polycythemia 10.8 CD40LG CRP
17 cannabis dependence 10.8 CD40LG CRP
18 brown's tendon sheath syndrome 10.8 APOH CD40LG
19 alcoholic gastritis 10.8 APOH CD40LG
20 lockwood feingold syndrome 10.8 APOH CD40LG
21 rubella 10.7 APOH CD40LG
22 leiomyosarcoma 10.7 CD40LG CRP
23 pancreatic vasoactive intestinal peptide producing tumor 10.7 CD40LG CRP
24 dumping syndrome 10.7 CD40LG IFNG
25 chronic mucocutaneous candidiasis 10.7 CD40LG CRP
26 anthracosilicosis 10.7 HLA-DRB1 IFNG
27 hypertensive heart disease 10.6 CD40LG CRP
28 mosaic trisomy 1 10.6 HLA-DRB1 IFNG
29 median arcuate ligament syndrome 10.6 CD40LG SMUG1
30 rocky mountain spotted fever 10.6 CD40LG CRP
31 clopidogrel resistance 10.6 HLA-DRB1 PTPN22
32 alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome 10.6 HLA-DRB1 PTPN22
33 pseudovascular skin squamous cell carcinoma 10.6 CD40LG TNFRSF10A
34 nodular ganglioneuroblastoma 10.6 CRP SMUG1
35 compensatory emphysema 10.5 CCL2 CD40LG CRP
36 ocular motility disease 10.5 CD40LG SMUG1
37 temporomandibular ankylosis 10.5 CD40LG CRP IFNG
38 louping ill 10.5 CCL2 CRP IFNG
39 partial sensory epilepsy 10.5 APOH CD40LG CRP
40 kidney carcinoma in situ 10.5 CD40LG TNFRSF10A
41 blood group incompatibility 10.5 APOH CD40LG HLA-DRB1
42 left bundle branch hemiblock 10.5 CD40LG HLA-DRB1 IFNG
43 cavernous lymphangioma 10.5 APOH CD40LG
44 breast hemangiopericytoma 10.5 HLA-DRB1 TNFRSF10A
45 myasthenia gravis 10.4 CD40LG PTPN22
46 rheumatic heart disease 10.4 CD40LG CRP SMUG1
47 parovarian cyst 10.4 CCL2 SERPINA3
48 porokeratosis 3, multiple types 10.4 CRP IL1RN
49 streptococcal meningitis 10.4 APOH CCL2
50 indian tick typhus 10.3 CCL5 CD40LG IFNG

Comorbidity relations with Temporal Arteritis via Phenotypic Disease Network (PDN): (show all 24)


Active Peptic Ulcer Disease Acute Cystitis
Bronchitis Cerebral Arteritis
Chronic Myocardial Ischemia Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Ischemic Heart Disease
Left Ventricular Outflow Tract Obstruction Mitral Valve Disease
Nonarteritic Anterior Ischemic Optic Neuropathy Optic Neuritis
Osteoporosis Pituitary Adenoma, Acth-Secreting
Polymyositis Premature Ovarian Failure 7
Rheumatoid Arthritis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Temporal Arteritis:



Diseases related to Temporal Arteritis

Symptoms & Phenotypes for Temporal Arteritis

Symptoms via clinical synopsis from OMIM:

54

Eyes:
blindness
retinal arteritis

Lab:
elevated sedimentation rate

Vascular:
temporal arteritis
giant cell arteritis
polymyalgia rheumatica (pmr)

Misc:
response to adrenal glucocorticoids


Clinical features from OMIM:

187360

Human phenotypes related to Temporal Arteritis:

56 32 (show top 50) (show all 58)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 visual impairment 56 32 frequent (33%) Frequent (79-30%) HP:0000505
2 optic atrophy 56 32 occasional (7.5%) Occasional (29-5%) HP:0000648
3 nystagmus 56 32 occasional (7.5%) Occasional (29-5%) HP:0000639
4 ataxia 56 32 occasional (7.5%) Occasional (29-5%) HP:0001251
5 diplopia 56 32 occasional (7.5%) Occasional (29-5%) HP:0000651
6 headache 56 32 hallmark (90%) Very frequent (99-80%) HP:0002315
7 ptosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000508
8 hematuria 56 32 occasional (7.5%) Occasional (29-5%) HP:0000790
9 alopecia 56 32 frequent (33%) Frequent (79-30%) HP:0001596
10 fatigue 56 32 hallmark (90%) Very frequent (99-80%) HP:0012378
11 muscle weakness 56 32 occasional (7.5%) Occasional (29-5%) HP:0001324
12 renal insufficiency 56 32 occasional (7.5%) Occasional (29-5%) HP:0000083
13 aortic dissection 56 32 occasional (7.5%) Occasional (29-5%) HP:0002647
14 depression 56 32 frequent (33%) Frequent (79-30%) HP:0000716
15 pericarditis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001701
16 arthritis 56 32 frequent (33%) Frequent (79-30%) HP:0001369
17 myalgia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003326
18 epistaxis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000421
19 fever 56 32 hallmark (90%) Very frequent (99-80%) HP:0001945
20 sudden cardiac death 56 32 occasional (7.5%) Occasional (29-5%) HP:0001645
21 joint stiffness 56 32 hallmark (90%) Very frequent (99-80%) HP:0001387
22 abdominal pain 56 32 occasional (7.5%) Occasional (29-5%) HP:0002027
23 hepatic failure 56 32 occasional (7.5%) Occasional (29-5%) HP:0001399
24 cough 56 32 occasional (7.5%) Occasional (29-5%) HP:0012735
25 vertigo 56 32 occasional (7.5%) Occasional (29-5%) HP:0002321
26 diabetes insipidus 56 32 occasional (7.5%) Occasional (29-5%) HP:0000873
27 weight loss 56 32 hallmark (90%) Very frequent (99-80%) HP:0001824
28 hyperhidrosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000975
29 ophthalmoparesis 56 32 frequent (33%) Frequent (79-30%) HP:0000597
30 vasculitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0002633
31 chewing difficulties 56 32 hallmark (90%) Very frequent (99-80%) HP:0005216
32 gangrene 56 32 occasional (7.5%) Occasional (29-5%) HP:0100758
33 arthralgia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002829
34 visual loss 56 32 occasional (7.5%) Occasional (29-5%) HP:0000572
35 arterial thrombosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0004420
36 visual field defect 56 32 occasional (7.5%) Occasional (29-5%) HP:0001123
37 anorexia 56 32 hallmark (90%) Very frequent (99-80%) HP:0002039
38 glossitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000206
39 cerebral ischemia 56 32 hallmark (90%) Very frequent (99-80%) HP:0002637
40 meningitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001287
41 paresthesia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003401
42 elevated erythrocyte sedimentation rate 56 32 frequent (33%) Frequent (79-30%) HP:0003565
43 gastrointestinal infarctions 56 32 occasional (7.5%) Occasional (29-5%) HP:0005244
44 abnormality of the pleura 56 32 occasional (7.5%) Occasional (29-5%) HP:0002103
45 skin ulcer 56 32 occasional (7.5%) Occasional (29-5%) HP:0200042
46 amaurosis fugax 56 32 occasional (7.5%) Occasional (29-5%) HP:0100576
47 conductive hearing impairment 56 32 occasional (7.5%) Occasional (29-5%) HP:0000405
48 abnormality of thrombocytes 56 32 occasional (7.5%) Occasional (29-5%) HP:0001872
49 recurrent pharyngitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0100776
50 mediastinal lymphadenopathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0100721

UMLS symptoms related to Temporal Arteritis:


back pain, exanthema, muscle cramp, muscle rigidity, muscle spasticity, pruritus, sciatica, muscle weakness, myalgia, angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Temporal Arteritis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 CCL2 CCL5 CD40LG CRP IFNG IL1RN

Drugs & Therapeutics for Temporal Arteritis

Drugs for Temporal Arteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
2 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
3 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
4 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
5 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
6 Hormones Phase 4,Phase 3,Phase 2,Phase 1
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Omega 3 Fatty Acid Nutraceutical Phase 4
9
Infliximab Approved Phase 3,Phase 2 170277-31-3
10
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
12
Hydroxychloroquine Approved Phase 3 118-42-3 3652
13
Adalimumab Approved Phase 3 331731-18-1 16219006
14
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
15
Etanercept Approved, Investigational Phase 3 185243-69-0
16
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
17
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
18
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
22 Antirheumatic Agents Phase 3,Phase 2
23 Dermatologic Agents Phase 3,Phase 2,Phase 1
24 Gastrointestinal Agents Phase 3,Phase 2
25 Anti-Infective Agents Phase 3
26 Antiemetics Phase 2, Phase 3
27 Autonomic Agents Phase 2, Phase 3
28 Methylprednisolone acetate Phase 2, Phase 3
29 Methylprednisolone Hemisuccinate Phase 2, Phase 3
30 Neuroprotective Agents Phase 2, Phase 3
31 Peripheral Nervous System Agents Phase 2, Phase 3
32 Prednisolone acetate Phase 2, Phase 3
33 Prednisolone hemisuccinate Phase 2, Phase 3
34 Prednisolone phosphate Phase 2, Phase 3
35 Protective Agents Phase 2, Phase 3
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
37 Pharmaceutical Solutions Phase 3
38 Antimalarials Phase 3
39 Antiparasitic Agents Phase 3
40 Antiprotozoal Agents Phase 3
41 Bone Density Conservation Agents Phase 3
42 Hydroxycholecalciferols Phase 3
43 Micronutrients Phase 3
44 Trace Elements Phase 3
45 Vitamins Phase 3
46 Analgesics Phase 3
47 Analgesics, Non-Narcotic Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 3
49 Antimetabolites Phase 3,Phase 2
50 Antimetabolites, Antineoplastic Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 66)

id Name Status NCT ID Phase Drugs
1 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
2 Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients Completed NCT01169597 Phase 4 prednisone
3 Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. Recruiting NCT03244709 Phase 4 Tocilizumab
4 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
5 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica Unknown status NCT01423591 Phase 3 infliximab;inactive powder
6 Hydroxychloroquine in Giant Cell Arteritis Completed NCT00430807 Phase 3 hydroxychloroquine/placebo
7 HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis Completed NCT00305539 Phase 3 adalimumab;placebo
8 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
9 Timed Release Tablet Prednisone in Polymyalgia Rheumatica Completed NCT00836810 Phase 2, Phase 3 Timed Release Tablet Prednisone;Prednisolone
10 Etanercept Treatment in the Early Course of Polymyalgia Rheumatica Completed NCT00524381 Phase 3 Etanercept (Enbrel);Sodium chloride (placebo)
11 Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Recruiting NCT02531633 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone;Placebo to match prednisone
12 Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Recruiting NCT02908217 Phase 3 Tocilizumab;Placebo
13 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Active, not recruiting NCT01791153 Phase 3 Tocilizumab;Prednisone;Tocilizumab Placebo;Prednisone Placebo;Corticosteroids;Methotrexate
14 Giant Cell Arteritis and Anakinra Trial Not yet recruiting NCT02902731 Phase 3 PLACEBO;ANAKINRA
15 An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Not yet recruiting NCT03202368 Phase 3 Tocilizumab
16 A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Not yet recruiting NCT03263715 Phase 3 Tocilizumab Prefilled Syringe [Actemra];Placebos;Glucocorticoids
17 Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Not yet recruiting NCT02899026 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone /Prednisone placebo
18 A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR Terminated NCT01821040 Phase 3 Lodotra®;Prednisone IR (immediate release)
19 A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) Withdrawn NCT03192969 Phase 3 Abatacept;Glucocorticoid Treatment
20 Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Horton's Disease: Proof of Concept Study. Unknown status NCT01910038 Phase 2 corticoids+ tocilizumab 8mg/Kg/month
21 Tocilizumab for Patients With Giant Cell Arteritis Completed NCT01450137 Phase 2 Tocilizumab + Glucocorticoids (GCs);Placebo + Glucocorticoids (GCs)
22 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed NCT00556439 Phase 2 Abatacept;Placebo
23 Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis Completed NCT00004686 Phase 2 methotrexate;prednisone
24 Tocilizumab Effect iN pOlymyalgia Rheumatica Completed NCT01713842 Phase 2 TCZ
25 Study of Tocilizumab to Treat Polymyalgia Rheumatica Completed NCT01396317 Phase 2 Tocilizumab
26 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
27 Ustekinumab for the Treatment of Giant Cell Arteritis Recruiting NCT02955147 Phase 1, Phase 2 Ustekinumab;Prednisone
28 Baricitinib in Relapsing Giant Cell Arteritis Recruiting NCT03026504 Phase 2 Baricitinib
29 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis Terminated NCT00076726 Phase 2 Infliximab
30 Delayed Release Prednisone in PMR Terminated NCT02702778 Phase 2 Delayed-Release (DR) Prednisone;Immediate Release (IR) Prednisone
31 A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica Terminated NCT01364389 Phase 2 AIN457;ACZ885;Prednisone;Placebo
32 MRI Superficial Temporal Artery Completed NCT00188448 Phase 1
33 Diagnostic Study of Temporal Arteritis Unknown status NCT01130857
34 Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis Unknown status NCT00361192 Early Phase 1
35 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
36 Study of the T CD8 Immune Response in Horton's Disease Unknown status NCT02158208
37 Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica Unknown status NCT00982332 Betamethasone;isotonic sodium chloride solution (placebo)
38 Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD) Unknown status NCT02065297
39 FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment Completed NCT03285945 PET3;PET10
40 Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL) Completed NCT00974883
41 Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis Completed NCT01795456
42 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
43 Impact of Vasculitis on Employment and Income Completed NCT02476292
44 Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica Completed NCT02888496 tocilizumab
45 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
46 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
47 Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS Completed NCT02042092
48 Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica Completed NCT00847236
49 Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis Recruiting NCT00315497
50 Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis Recruiting NCT01588483

Search NIH Clinical Center for Temporal Arteritis

Cochrane evidence based reviews: giant cell arteritis

Genetic Tests for Temporal Arteritis

Anatomical Context for Temporal Arteritis

MalaCards organs/tissues related to Temporal Arteritis:

39
Testes, Tongue, Skin, Brain, Spinal Cord, Bone, Neutrophil

Publications for Temporal Arteritis

Articles related to Temporal Arteritis:

(show top 50) (show all 541)
id Title Authors Year
1
Stroke and temporal arteritis: A study of 6 cases. ( 28869044 )
2017
2
Studies on the Histopathology of Temporal Arteritis. ( 28275606 )
2017
3
Metaplastic ossification of the temporal artery with osteoclast-like giant cells: a mimicker of giant cell (temporal) arteritis. ( 28315516 )
2017
4
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? ( 28899801 )
2017
5
Temporal Arteritis With Arteritic Anterior Ischemic Optic Neuropathy is Bilateral Until Proven Otherwise: Response. ( 27855129 )
2016
6
Temporal arteritis with erythrocyte sedimentation rate <50 mm/h: a clinical reminder. ( 26966355 )
2016
7
When a temporal artery biopsy reveals a diagnosis other than temporal arteritis: eosinophilic granulomatosis with polyangiitis. ( 27316282 )
2016
8
Preserved Visual Acuity in Anterior Ischemic Optic Neuropathy Secondary to Giant Cell (temporal) Arteritis. ( 26958148 )
2016
9
The Temporal Arteritis Proforma: Should cough be included? ( 27592336 )
2016
10
Bilateral Blindness in a Patient With Temporal Arteritis After Wisdom Tooth Extraction. ( 26854772 )
2016
11
Hypertrophic Pachymeningitis as a Potential Cause of Headache Associated with Temporal Arteritis. ( 26935376 )
2016
12
Extracranial cutaneous manifestation of temporal arteritis--a case of erythematous plaques on the legs. ( 26713645 )
2016
13
Is All Inflammation within Temporal Artery Biopsies Temporal Arteritis? ( 27445262 )
2016
14
Juvenile temporal arteritis with eosinophilia associated with systemic sclerosis. ( 27401371 )
2016
15
Giant cell or temporal arteritis? ( 28691446 )
2016
16
VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity. ( 26688577 )
2016
17
The role of ultrasound in the diagnosis of temporal arteritis. ( 25890932 )
2015
18
Magnetic Resonance Imaging of Temporal Arteritis: A Case Report. ( 25758708 )
2015
19
The effect of temporal artery biopsy on the treatment of temporal arteritis. ( 25457237 )
2015
20
Elderly woman with headache. Giant cell arteritis/temporal arteritis. ( 25910765 )
2015
21
Annular Elastolytic Giant Cell Granuloma and Temporal Arteritis Following Herpes Zoster. ( 26861435 )
2015
22
Calciphylaxis of the temporal artery masquerading as temporal arteritis: a case presentation and review of the literature. ( 25903821 )
2015
23
Monckeberg's Arteriosclerosis in Temporal Arteritis Suspect. ( 26711297 )
2015
24
Waldenstrom Macroglobulinemia Mimicking Temporal Arteritis. ( 25996301 )
2015
25
Fatal Calciphylaxis Presenting as Polymyalgia Rheumatica and Temporal Arteritis. ( 26583498 )
2015
26
Giant cell arteritis (temporal arteritis) revisited. ( 26448217 )
2015
27
Annular Elastolytic Giant Cell Granuloma and Temporal Arteritis Following Herpes Zoster. ( 26861422 )
2015
28
Giant Cell Arteritis of the Female Genital Tract With Occult Temporal Arteritis and Marginal Zone Lymphoma Harboring Novel 20q Deletion: A Case Report and Literature Review. ( 26353853 )
2015
29
A case of temporal arteritis in Filippino Lippi's (1459-1504) Saint Frediano? ( 26638160 )
2015
30
A rare case of temporal arteritis with rheumatoid arthritis and interstitial lung disease mimicking pulpo-periodontal pathology. ( 25210275 )
2014
31
Temporal Artery Calciphylaxis Presenting as Temporal Arteritis in a Case of Rhinoorbitocerebral Mucormycosis. ( 24853118 )
2014
32
Primary systemic Al amyloidosis presenting as temporal arteritis. ( 24551471 )
2014
33
Perivascular Marginal Zone Lymphoma Mimicking Temporal Arteritis. ( 25361636 )
2014
34
High-resolution color-coded ultrasonography findings of subacute temporal arteritis with ulcerating skin lesions. ( 25047586 )
2014
35
Polyarteritis nodosa mimicking giant cell (temporal) arteritis. ( 25030583 )
2014
36
Stellate ganglion block as an early intervention in sympathetically maintained headache and orofacial pain caused by temporal arteritis. ( 23332006 )
2013
37
Vertebrobasilar Infarction Related to Giant Cell (Temporal) Arteritis: Case Report. ( 24390182 )
2013
38
Morphological features of temporal arteritis. ( 23543964 )
2013
39
Scalp necrosis in temporal arteritis: abrupt termination of the superficial temporal artery as a possible precursor. ( 23331479 )
2013
40
Juvenile temporal arteritis. ( 23294490 )
2013
41
The activation pattern of macrophages in giant cell (temporal) arteritis and primary angiitis of the central nervous system. ( 24354510 )
2013
42
Temporal arteritis in the young. ( 23142255 )
2013
43
Temporal arteritis: improving patient evaluation with a new protocol. ( 23596371 )
2013
44
Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case. ( 24252028 )
2013
45
Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. ( 23300333 )
2013
46
Temporal arteritis in a young patient. ( 24143876 )
2013
47
Amyloid deposits in temporal artery mimicking temporal arteritis in a patient with multiple myeloma. ( 24232087 )
2013
48
Our approach to the diagnosis and treatment of polymyalgia rheumatica and giant cell (temporal) arteritis. ( 23240123 )
2012
49
Association between human papillomavirus DNA and temporal arteritis. ( 22831396 )
2012
50
Corneal endothelial decompansation and ocular hypotony in a case with temporal arteritis. ( 23041790 )
2012

Variations for Temporal Arteritis

Expression for Temporal Arteritis

Search GEO for disease gene expression data for Temporal Arteritis.

Pathways for Temporal Arteritis

GO Terms for Temporal Arteritis

Cellular components related to Temporal Arteritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 APOH CCL2 CCL5 CD40LG CRP IFNG
2 external side of plasma membrane GO:0009897 9.46 CD40LG HLA-DRB1 IFNG IL6
3 extracellular space GO:0005615 9.28 APOH CCL2 CCL5 CD40LG CRP IFNG

Biological processes related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 CRP IFNG IL6 PTPN22
2 T cell receptor signaling pathway GO:0050852 9.81 HLA-DRB1 IFNG PTPN22
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.81 CCL2 CCL5 IL6 PTPN22
4 response to lipopolysaccharide GO:0032496 9.8 CCL2 IL6 PTPN22 TNFRSF10A
5 cellular response to lipopolysaccharide GO:0071222 9.79 CCL2 IFNG IL6
6 cellular response to tumor necrosis factor GO:0071356 9.78 CCL2 CCL5 IL6
7 cellular response to interleukin-1 GO:0071347 9.74 CCL2 CCL5 IL6
8 response to glucocorticoid GO:0051384 9.73 CCL2 IL1RN IL6
9 neutrophil chemotaxis GO:0030593 9.72 CCL2 CCL5 IFNG
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CCL5 IFNG IL6
11 humoral immune response GO:0006959 9.7 CCL2 IFNG IL6
12 positive regulation of cell adhesion GO:0045785 9.65 CCL2 CCL5 IFNG
13 defense response to protozoan GO:0042832 9.64 IFNG IL6
14 positive regulation of JAK-STAT cascade GO:0046427 9.63 CCL5 IL6
15 positive regulation of monocyte chemotaxis GO:0090026 9.62 CCL2 CCL5
16 positive regulation of macrophage chemotaxis GO:0010759 9.6 CCL2 CCL5
17 macrophage chemotaxis GO:0048246 9.59 CCL2 CCL5
18 positive regulation of protein import into nucleus, translocation GO:0033160 9.58 IFNG IL6
19 negative regulation of lipid storage GO:0010888 9.58 CRP IL6
20 monocyte chemotaxis GO:0002548 9.58 CCL2 CCL5 IL6
21 immune response GO:0006955 9.56 CCL2 CCL5 CD40LG HLA-DRB1 IFNG IL1RN
22 acute-phase response GO:0006953 9.5 CRP IL6 SERPINA3
23 regulation of vascular endothelial growth factor production GO:0010574 9.46 CCL2 IL6
24 positive regulation of T cell proliferation GO:0042102 9.46 CCL5 CD40LG IFNG IL6
25 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.43 IL1RN IL6
26 lipopolysaccharide-mediated signaling pathway GO:0031663 9.43 CCL2 CCL5 PTPN22
27 neutrophil apoptotic process GO:0001781 9.37 IFNG IL6
28 inflammatory response GO:0006954 9.23 CCL2 CCL5 CD40LG CRP IL1RN IL6

Molecular functions related to Temporal Arteritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CCL2 CCL5 CD40LG IFNG IL1RN IL6

Sources for Temporal Arteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....